Drugs for Rare Diseases – Alberta Agreement

On December 5, 2024, the Governments of Canada and Alberta signed an agreement to invest over $162 million in improving access to new drugs for rare diseases. This agreement is part of the National Strategy for Drugs for Rare Disease (DRD) and aims to enhance access to existing drugs, early diagnosis, and screening for rare diseases. Three specific drugs will be made available to Albertans: Poteligeo, Oxlumo, and Epkinly.